Disc Medicine Inc (IRON) - News Archive

CSIMarket.com Chronic Kidney Disease (CKD) is a global health challenge marked by progressive loss of kidney function over time, often culminating in significant morbidity and mortality. Anemia associated with CKD is a...

: Disc Medicine, Inc. a pioneering clinical-stage biopharmaceutical firm, has recently reported encouraging outcomes from its Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the APOLLO post-mar...

Disc Medicine Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for serious hematologic diseases, has recently announced a significant financial milestone that positions the compa...

Emerging Innovations in Hematologic Disease Treatment: A Spotlight on Disc Medicine Disc Medicine, Inc. a clinical-stage biopharmaceutical company operating in the niche of hematologic diseases, is making significant st...

Disc Medicine, Inc. a clinical-stage biopharmaceutical company, recently announced to present new clinical data from its ongoing Phase 1b trial of DISC-0974 at the 2024 American Society of Nephrology (ASN) Kidney Week....

In a significant move towards advancing its mission of revolutionizing the treatment landscape for serious hematologic diseases, Disc Medicine, Inc., a prominent clinical-stage biopharmaceutical company, has announced t...

Positive Clinical Data Across Disc Medicine s Portfolio Highlight Potential Advances in Hematologic Treatments BackgroundDisc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company, has made significa...

Following the recent announcement by Disc Medicine, Inc. (NASDAQ:IRON), a leading clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for patients affli...

Disc Medicine, Inc. (NASDAQ:IRON) has recently presented updated positive results from the phase 2 BEACON study of bitopertin, an orally administered glycine transporter 1 (GlyT1) inhibitor, at the 65th American Society...

WATERTOWN, Mass., Nov. 14, 2023 - Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients suffering from severe hematologic diseases, has r...